(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 61.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Cormedix's revenue in 2025 is $82,553,827.On average, 2 Wall Street analysts forecast CRMD's revenue for 2025 to be $15,057,413,421, with the lowest CRMD revenue forecast at $13,225,808,505, and the highest CRMD revenue forecast at $16,889,018,338. On average, 3 Wall Street analysts forecast CRMD's revenue for 2026 to be $21,151,526,857, with the lowest CRMD revenue forecast at $16,888,340,091, and the highest CRMD revenue forecast at $28,050,244,223.
In 2027, CRMD is forecast to generate $22,416,049,800 in revenue, with the lowest revenue forecast at $22,056,579,107 and the highest revenue forecast at $22,775,520,492.